Mass cytometry reveals cladribine-induced resets among innate lymphoid cells in multiple sclerosis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 11 2022
27 11 2022
Historique:
received:
08
07
2022
accepted:
17
11
2022
entrez:
27
11
2022
pubmed:
28
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
Here we present a comprehensive mass cytometry analysis of peripheral innate lymphoid cell (ILC) subsets in relapsing/remitting MS (RRMS) patients prior to and after onset of cladribine tablets (CladT). ILC analysis was conducted on CyTOF data from peripheral blood mononuclear cells (PBMC) of MS patients before, 2 and 6 months after onset of CladT, and non-MS controls. Dimensionality reduction was used for immunophenotyping ILC subsets. CladT reduced all ILC subsets, except for CD56bright NK cells and ILC2. Furthermore, CD38+ NK cell and CCR6+ ILC3 were excluded from CladT-induced immune cell reductions. Post-CladT replenishment by immature ILC was noted by increased CD5+ ILC1 proportions at 2 months, and boosted CD38-CD56bright NK cell numbers at 6 months. CladT induce immune cell depletion among ILC but exclude CD56bright NK cells and ILC2 subsets, as well as CD38+ NK cell and CCR6+ ILC3 immunophenotypes. Post-CladT ILC expansions indicate ILC reconstitution towards a more tolerant immune system phenotype.
Identifiants
pubmed: 36437270
doi: 10.1038/s41598-022-24617-4
pii: 10.1038/s41598-022-24617-4
pmc: PMC9701791
doi:
Substances chimiques
Cladribine
47M74X9YT5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20411Subventions
Organisme : Multiple Sclerosis Research Australia
ID : 17-0140
Organisme : Merck
ID : MS700568_0030
Informations de copyright
© 2022. The Author(s).
Références
Mult Scler. 2017 Oct;23(11):1479-1487
pubmed: 28273762
Sci Transl Med. 2012 Aug 1;4(145):145ra106
pubmed: 22855463
Nat Rev Neurol. 2020 Jan;16(1):56-62
pubmed: 31649335
Semin Immunopathol. 2018 Jul;40(4):393-406
pubmed: 29568972
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
J Neurol. 2018 May;265(5):1199-1209
pubmed: 29550884
J Neuroimmune Pharmacol. 2021 Apr 14;:
pubmed: 33851318
Nat Methods. 2019 Mar;16(3):243-245
pubmed: 30742040
Mult Scler. 2016 Jul;22(8):1013-20
pubmed: 26453677
J Clin Med. 2020 May 13;9(5):
pubmed: 32414131
Nature. 2021 Dec;600(7890):707-712
pubmed: 34853467
Nat Med. 2015 Jul;21(7):698-708
pubmed: 26121198
Mult Scler. 2017 Jun;23(7):1025-1030
pubmed: 27481205
Proc Natl Acad Sci U S A. 2016 May 24;113(21):E2973-82
pubmed: 27162345
Mol Aspects Med. 2021 Aug;80:100963
pubmed: 33726947
Ann Clin Transl Neurol. 2020 Nov;7(11):2199-2212
pubmed: 33002321
Int J Mol Sci. 2021 Aug 04;22(16):
pubmed: 34445097
Cytometry A. 2022 Mar;101(3):237-253
pubmed: 33840138
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
Neuron. 2018 Feb 21;97(4):742-768
pubmed: 29470968
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
Immunol Cell Biol. 2022 Jul;100(6):453-467
pubmed: 35416319
Clin Transl Immunology. 2021 Feb 01;10(2):e1250
pubmed: 33552511
Eur J Neurol. 2009 Mar;16(3):409-12
pubmed: 19175384
Front Immunol. 2020 Apr 24;11:714
pubmed: 32391016
Mult Scler Relat Disord. 2021 Jul;52:102962
pubmed: 33901971
Nervenarzt. 2018 Aug;89(8):895-907
pubmed: 29523912
Front Immunol. 2016 Dec 19;7:606
pubmed: 28066417
J Neuroimmunol. 2020 Dec 15;349:577392
pubmed: 33007647
Front Immunol. 2021 Nov 18;12:752104
pubmed: 34867984